Sentinel Node Lymph Node Surgery After Neoadjuvant Therapy: Principles and Techniques.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31342394.
- Also identified by DOI 10.1245/s10434-019-07591-6.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Surgical management of the axilla in breast cancer has been a topic of great interest. While sentinel lymph node biopsy (SLNB) is an established approach for patients undergoing surgical treatment as the first element of their care, there is continued debate regarding surgical management of the axilla in patients receiving neoadjuvant chemotherapy (NAC). In clinically node-negative patients, it has been debated whether or not SLNB should be performed before chemotherapy to accurately determine the clinical stage, or after chemotherapy, thus prioritizing the response to therapy and potentially minimizing axillary surgery. Node-positive patients have undergone axillary lymph node dissection in the past, however this paradigm has been challenged in recent years. Thus, surgeons must understand the importance of accurate axillary information both before and after NAC, and its role in multidisciplinary planning. We present a summary of the data surrounding axillary management in patients receiving NAC, and recommendations for surgical technique.
Medical subject headings
- Breast Neoplasms
- Lymph Node Excision
- Neoadjuvant Therapy
- Practice Guidelines as Topic
- Sentinel Lymph Node
- Sentinel Lymph Node Biopsy